Healthcare M&A Dips: August Sees 9% Decline in Deals

Healthcare M&A Dips: August Sees 9% Decline in Deals

Healthcare mergers & acquisitions (M&A) deal activity declined in August 2024, according to data captured in the LevinPro HC database. Totaling 161 transactions throughout the month, this is an approximately 9% decrease from July 2024, when 177 healthcare transactions were reported. The deal volume of the entirety of August 2024 accounts for nearly 12% of the 1,352 healthcare transactions announced since the start of the year.  While most sectors reported similar numbers between July and August, markets such as Other Services and Biotechnology & Pharmaceuticals (Biopharma) saw a steep decline. The Biopharma space declined from 18 transactions in July 2024 to 14 in August... Read More »
Most Active States for Healthcare Services M&A in 2024 (So Far)

Most Active States for Healthcare Services M&A in 2024 (So Far)

As the healthcare industry continues to evolve, mergers and acquisitions (M&As) have become a strategic tool for providers to expand their reach, enhance services and improve efficiency. This year, certain states have emerged as particularly active hubs for healthcare services M&A. The healthcare services sectors included in this report include Behavioral Health Care, Home Health & Hospice, Hospitals, Laboratories, MRI & Dialysis, Long-Term Care, Managed Care, Physician Medical Groups, Rehabilitation and Other Services (a mix of companies providing ancillary healthcare services, or those relating to healthcare). This analysis examines the most active U.S. states and regions... Read More »
M&A Deal Volume Increases in July 2024: A Conversation with Andre Ulloa and Mark Thomas

M&A Deal Volume Increases in July 2024: A Conversation with Andre Ulloa and Mark Thomas

In July 2024, there were 175 healthcare transactions reported, marking an 8% increase from June 2024 when 162 deals were announced and a 4% from July 2023 when 168 healthcare acquisitions were reported. The deal volume of July 2024 accounts for nearly 15% of the 1,190 healthcare transactions announced since the start of 2024. The most active sector was Other Services with 56 acquisitions. Other Services is a catch-all/miscellaneous sector that encompasses a variety of transactions from medical outpatient buildings (MOBs) to contract development manufacturing organizations (CDMOs). In July 2024, there were 19 MOB transactions, four infusion service acquisitions and two CDMO deals. The... Read More »
Why Invest in the Health Clinic Market

Why Invest in the Health Clinic Market

We sat down and spoke with industry expert Andre Ulloa, Partner and Executive Advisor of M&A Healthcare Advisors, to discuss the key considerations investors should know before investing in the health clinic market. Ulloa sheds light on the factors driving the recent surge in health clinic investment, and what’s to come for this booming market. What is a Health Clinic?  A health clinic, also called a walk-in clinic, is a convenient option for immediate, non-emergency medical care. These types of clinics can treat a wide range of conditions, such as the flu, strep throat, small cuts and skin infections. They can also provide services like physical exams, immunizations and similar... Read More »
Navigating Labor Headwinds in Home Health

Navigating Labor Headwinds in Home Health

More than three-quarters of Americans ages 50 and older want to age in place, according to an AARP survey. This comes as The U.S. Administration on Community Living projects the number of Americans aged 65 and older will rise to 80.8 million by 2040, creating significant demand for home health delivery models in the United States. But now, with the HH&H sector approaching a projected global shortage of 10 million health workers by 2030, according to the World Health Organization, the labor issues we’re already seeing in the space are only going to worsen.  The labor issues have profound implications for M&A activity within the sector. According to LevinPro HC data, deal volume in... Read More »
Noteworthy Deals of The Second Quarter of 2023

Noteworthy Deals of The Second Quarter of 2023

With 586 transactions in the second quarter of 2023, we want to take a moment to look at several that are interesting, whether in purchase price or size of assets.  Merck & Co. Acquires Prometheus Biosciences  On April 17, Merck & Co announced that it acquired Prometheus Biosciences for $10.8 billion. Prometheus Biosciences is a clinical-stage biotechnology company that specializes in treating immune-mediated diseases. This acquisition represents the largest purchase price of the quarter, regardless of sector. Robert M. Davis, chairman and chief executive officer of Merck had this to say.  “The Prometheus acquisition accelerates our growing presence in immunology,... Read More »